Our study suggested that one consequence of DNMT1 targeting by gDEC is the upregulation of KMTs, which could mediate the activation of tumor-suppressing programs and contribute to the overall prostate cancer phenotype change and anticancer effect. The gene discussed is DNMT1; the disease is prostate cancer.